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Key Points
• Accurate GZL
diagnosis remains
challenging, with
.60% of patients with
presumed GZL having
the diagnosis reclassi-
fied on consensus
review.
• Treatment with DLBCL-
based therapy appears
most effective for GZL
(including R-CHOP);
however, new thera-
pies are needed to
improve outcomes.
Gray zone lymphoma (GZL) is described as sharing features with classical Hodgkin lymphoma
(cHL) and diffuse large B-cell lymphoma (DLBCL). However, there remains complexity in
establishing diagnosis, delineating prognosis, and determining optimum therapy. Sixty-eight
cases diagnosed as GZL across 15 North American academic centers were evaluated by central
pathology review to achieve consensus. Of these, only 26 (38%) were conﬁrmed as GZL.
Morphology was critical to GZL consensus diagnosis (eg, tumor cell richness); immunohisto-
chemistry showeduniversalB-cell derivation, frequent CD30expression, and rareEpstein-Barr
virus (EBV) positivity (CD201, 83%; PAX51, 100%; BCL61, 20%; MUM11, 100%; CD301, 92%;
EBV1, 4%). Forty-two cases were reclassiﬁed: nodular sclerosis (NS) cHL, n 5 27 (including
n 5 10 NS grade 2); lymphocyte predominant HL, n 5 4; DLBCL, n 5 4; EBV1 DLBCL, n 5 3;
primary mediastinal large BCL n 5 2; lymphocyte-rich cHL and BCL–not otherwise
speciﬁed, n5 1 each. GZL consensus-conﬁrmed vs reclassiﬁed cases, respectively, more often
had mediastinal disease (69% vs 41%; P 5 .038) and less likely more than 1 extranodal
site (0%vs 25%;P5 .019).With a 44-monthmedian follow-up, 3-year progression-free survival
(PFS) and overall survival for patients with conﬁrmed GZL were 39% and 95%, respectively,
vs 58% and 85%, respectively, for reclassiﬁed cases (P 5 .19 and P 5 .15, respectively).
Interestingly, NS grade 2 reclassiﬁed patients had similar PFS as GZL consensus-conﬁrmed
cases. For prognostication of GZL cases, hypoalbuminemia was a negative factor (3-year PFS,
12% vs 64%; P 5 .01), whereas frontline cyclophosphamide, doxorubicin, vincristine,
and prednisone 6 rituximab (CHOP6R) was associated with improved 3-year PFS (70% vs
20%; P5 .03); both factors remained signiﬁcant onmultivariate analysis. Altogether, accurate
diagnosis of GZL remains challenging, and improved therapeutic strategies are needed.
Submitted 15 June 2017; accepted 14 September 2017. DOI 10.1182/
bloodadvances.2017009472.
Presented in part at the 59th annual meeting of the American Society of Hematology,
Atlanta, GA, 9-12 December 2017; the 58th annual meeting of the American Society
of Hematology, San Diego, CA, 3-6 December 2016; and the 10th International
Symposium on Hodgkin Lymphoma, Cologne, Germany, 22-25 October 2016.
The full-text version of this article contains a data supplement.
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Introduction
Gray zone lymphoma (GZL) is an uncommon neoplasm initially
described in 2005.1 B-cell lymphoma, unclassifiable, with features
intermediate between diffuse large B-cell lymphoma (DLBCL) and
classical Hodgkin lymphoma (cHL), GZL was first recognized in the
World Health Organization (WHO) classification as a distinct entity
in 2008.2
Despite advances in immunophenotyping, molecular diagnostics,
and more exact morphology-based discrimination, the diagnosis of
GZL remains complex. In addition, initially described as primarily
involving the mediastinum,1,3,4 further analyses have elucidated
both primary mediastinal and nonmediastinal (systemic) clinical
disease presentations.5,6 Regardless of presentation, patients with
GZL have comparatively inferior survival rates compared with either
cHL or DLBCL.5,7-10 Thus, accurate diagnosis is imperative, and
development of new and improved therapies is critically needed.
A recent multicenter retrospective study described 112 GZL
cases diagnosed and treated in 19 North American academic
centers.5 However, central pathologic review was not conducted.
To better understand the diagnostic challenges and to delineate
useful morphologic and immunohistochemical features that may
facilitate accurate diagnosis of GZL, a comprehensive study with
detailed centralized pathologic review and associated analyses of
clinical data was undertaken.
Methods
For the current study, we obtained 73 cases previously diagnosed
as GZL across 15 US and Canadian academic medical centers for
centralized pathologic review. Institutional review boards of all
participating institutions approved the study. Slides were identified
from each center (ie, full sections/tumor blocks) and submitted
centrally. All cases were subjected to central pathology review by a
panel of 5 hematopathologists (M.P., S.P., J.A.F., J.H., and E.S.J.).
Each case was reviewed at the multiheaded scope and discussed
until consensus for morphologic and immunohistochemical features
and diagnosis was reached. Criteria for GZL diagnosis followed the
2016 WHO classification.11
Only cases diagnosed as GZL at initial presentation were consid-
ered; nearly all of the original cases had been examined by an
academic hematopathologist. From 73 cases, 5 were excluded for
insufficient material for morphologic evaluation or insufficient number
of neoplastic cells represented. These 5 cases included 2 splenec-
tomies with only rare scattered neoplastic cells, bone marrow biopsy
with extensive fibrosis and rare crushed neoplastic cells, gastroin-
testinal tract biopsy with a few neoplastic cells seen in the lamina
propria, and a minimal soft tissue fragment with rare neoplastic cells.
The remaining 68 cases were evaluated on the basis of hematoxylin
and eosin sections of routinely fixed and paraffin-embedded material.
Immunostained slides from the referring institutions were available for
review; additional stains were performed in selected cases at Tufts
Medical Center and at Massachusetts General Hospital.
The recommended immunohistochemical panel considered ade-
quate to diagnose GZL was performed in all cases and included
CD20, CD79a, PAX5, MUM1, CD30, CD15, CD3, and Epstein-Barr
virus (EBV) (EBV-encoded small RNA) in situ hybridization. This
staining panel was decided before the central pathology review, and
it was determined to be the most efficient and minimum panel
of stains to perform on all cases. BOB.1 and OCT2 were also
performed in a minority of cases. Beyond a tumor cell immunoprofile,
diagnostic morphologic criteria included tumor cell density, fibrosis,
necrosis, and the microenvironment. Immunohistochemical staining
intensity was scored on a semiquantitative basis by comparing
staining intensity of neoplastic cells with reactive cells on the scale
1 to 3 (weak, moderate, strong). Extent of staining was scored on
a scale of 1 to 4 (1 5 1%-25%; 2 5 25%-50%; 3 5 50%-75%;
45.75% of neoplastic cells). Staining was considered satisfactory
if background T and/or B cells were deemed positive.
Clinical data
Information on patient and diagnostic features, staging investiga-
tions, and treatment administered was provided by the patients’
institutional providers. Receipt of radiation therapy was not consid-
ered an event or progression. Therapy was not predetermined and
was given at the discretion of the treating physician. Bulky disease
was defined as any mass lesion 10 cm or larger, and primary refrac-
tory disease was defined as lack of at least a partial response to
frontline therapy or progressive disease documented less than 6
months from initial partial or complete response. In addition, response
was defined according to revised and current criteria (eg, including
fluorodeoxyglucose–positron emission tomography).12,13
Statistical analysis
Characteristics were compared using x2 test for categorical variables
and Wilcoxon rank-sum for medians. Covariates were collected and
comprised the data set on which univariate analyses for progression-
free survival (PFS) and overall survival (OS) were performed. PFS
was calculated from the date of diagnosis to date of death or
disease relapse/progression. OS was computed from the date of
diagnosis to the date of death. Patients without PFS or OS events
were censored at the time of last clinical follow-up. Survival
analyses were performed regardless of the amount or length of
therapy received. Three-year PFS and OS rates were estimated
through Kaplan-Meier method,14 whereas survival differences
were assessed using the log-rank test. Univariate associations
between clinical and laboratory factors and survival were derived
using the Cox proportional hazards model.15 Variables with a
P # .10 in univariate analyses were entered into the multivariate
Cox proportional hazards model in a stepwise fashion.16 Hazard
ratios (HRs) and their 95% confidence intervals (CIs) were
reported. All statistical analyses were conducted with SAS v9.2
(SAS Institute Inc., Cary, NC).
Results
Consensus classification
Among the 68 cases that were examined on consensus review, the
original diagnosis of GZL was confirmed in only 26 cases (38%).
Clinical descriptions of these bona fide GZL cases are detailed
in Table 1. The remaining 42 cases (62%) were reclassified as
depicted in supplemental Table 1. Morphologic and immunohisto-
chemical examples of a GZL case and 2 reclassified cases are
shown in Figure 1A-C.
GZL cases
All 26 GZL cases were of B-cell derivation (ie, positive for$1 B-cell
marker: CD20, CD79a, and/or PAX5). In general, neoplastic cells in
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the confirmed GZL cases were abundant, often occurring in
sheets, with tumor cells usually being large with centroblastic or
immunoblastic appearance and a high degree of pleomorphism. Most
were strongly CD20 positive (21/26; 81%), whereas other B-cell
markers were variable (Figure 1D). Detailed immunohistochemistry
data are described in supplemental Table 1. MUM1 was available for
evaluation in 22/26 cases andwas consistently strong (scores 3 or 4)
in all but 1 case (ie, 96% strong MUM1 positivity), with moderate
staining in the other case. In addition to strong CD20 positivity, most
cases were CD301 (24/26, 92%), including 4 CD202 cases. These
4 latter cases did not qualify for the diagnosis of cHL, in part based
on a lack of morphologic criteria characteristic for cHL; most
notably, absence of a more extensive inflammatory background and
cytomorphology resembling primary mediastinal large B-cell lym-
phoma (PMBL) with strong PAX5 staining. CD15 was scored as
positive (ie, at least 21) in 11/26 cases (42%); in 5 cases (19%),
CD15 was strongly expressed in all neoplastic cells along with strong
CD30 coexpression. CD3 was positive in bystander T cells only. Only
1 GZL case (4%) was EBV1. There was no morphologic and/or
immunophenotypic difference between GZL primarily occurring in
the mediastinum or involving peripheral sites (data not shown).
Reclassified cases
Altogether, 42 cases originally diagnosed as GZL were reclassified.
Themajority of these reclassified cases (27/42; 64%)were interpreted
by the panel as cHL NS, which included a subset of cases (10/27)
interpreted as cHL NS, grade 2 (cHL NS2), also referred to historically
as cHL NS with lymphocyte depletion.17,18 Most of these cases had
strong CD20 expression and relatively weaker CD30 expression
(supplemental Table 2). Four cases were reclassified as nodular
lymphocyte-predominant Hodgkin lymphoma. In contrast to cHL and
GZL, neoplastic cells of nodular lymphocyte predominant Hodgkin
lymphoma had a germinal center cell immunophenotype (ie, were
BCL-6 positive) and arose in altered follicles with admixed small
CD201 B-cells. Four of the reclassified cases were DLBCL NOS,
and 2 were diagnosed as PMBL. EBV-driven lymphoid proliferations
can morphologically and immunophenotypically overlap with cHL;
3 EBV-positive DLBCL cases were originally interpreted as GZL.
Patient characteristics
Detailed clinical information was available for 25 of the 26
consensus-confirmed GZL cases, which is detailed in Table 1. There
was a male predominance (male:female, 1.9:1), and the median age
of these patients with GZL was 37 years, with only 4/25 (16%) being
older than 60 years. Performance status was overall good, whereas a
majority of patients presented with anemia, elevated lactate de-
hydrogenase, and hypoalbuminemia. No patients had evidence or
more than 1 site of extranodal disease or bone marrow involvement,
Table 1. Baseline characteristics: GZL consensus confirmed cases
Characteristics n (%)
Patient characteristics
Median age 37 y (range, 19-72 y)
Sex
Male 17 (62)
Female 9 (38)
Performance status
0-1 24 (88)
2-4 2 (8)
NA 1 (4)
B symptoms
Yes 9 (35)
No 13 (50)
NA 4 (15)
Albumin
Normal 7 (27)
Low 14 (54)
NA 5 (19)
Hemoglobin
Decreased 15 (58)
Normal 10 (38)
NA 1 (4)
LDH
Normal 9 (35)
Elevated 15 (58)
NA 2 (7)
Disease characteristics
Mediastinal involvement/disease 18 (69)
Bone marrow involvement
Absent 25 (96)
Present 0 (0)
NA 1 (4)
Extranodal sites present
#1 25 (96)
.1 0 (0)
NA 1 (4)
Stage
I/II 17 (65)
III/IV 8 (31)
NA 1 (4)
Bulky disease
Yes 8 (31)
No 16 (62)
NA 2 (7)
IPI
0-2 17 (65)
3-5 5 (19)
NA 4 (16)
Table 1. (continued)
Characteristics n (%)
IPS
0-1 9 (35)
2-3 9 (35)
4-6 2 (7)
NA 6 (23)
LDH, lactate dehydrogenase; NA, not available.
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and nearly 70% had primary mediastinal presentation, with the
remaining patients having no evidence of mediastinal disease.
Approximately two-thirds of patients had early-stage disease, with
one-third having bulky disease (defined as .10 cm). For clinical
prognostic scoring, only a minority of patients had high International
Prognostic Index or International Prognostic Score.
Clinical differences between primary mediastinal GZL vs non-
mediastinal (systemic) GZL from the consensus-confirmed cases
included age (ie, 35 years vs 51 years, respectively; P 5 .05),
anemia at diagnosis (44% vs 87%, respectively; P 5 .08), stage I/II
disease at diagnosis (89% vs 46%, respectively; P 5 .03), and
presence of bulk disease (44% vs 0, respectively; P 5 .06).
Clinical features of the cases reclassified on consensus review
are depicted in supplemental Table 3. Male predominance
was more pronounced (ie, 3:1) in reclassified cases compared
with consensus GZL cases. Among reclassified cases, median
age was 44 years, and 22% of these patients were older than
60 years. In addition, fewer patients among the reclassified cases
had primary mediastinal disease (41% vs 69%; P 5 .038),
whereas a higher proportion had involvement of more than
1 extranodal site (25% vs 0; P 5 .019). A majority of patients with
reclassified lymphomas had advanced-stage disease (ie, 56%)
compared with GZL consensus cases; however, this was not
significant (P 5 .12).
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Figure 1. Consensus pathology. (A) Case example of consensus GZL diagnosis (B-cell lymphoma with features intermediate between diffuse large B-cell lymphoma and
classical Hodgkin lymphoma). Sheetlike proliferation of tumor cells resembling PMBL is seen in the top left panel. Focally, collections of eosinophils are noted (top right). The tumor
cells are strongly positive for CD20, CD30, and CD15 (bottom). (B) Reclassified case: cHL NS2. Representative images from 2 cases of cHL NS2 are shown. (Top) Characteristic
histology with a nodular growth pattern, fibrous bands, and a sheetlike growth of lacunar cells. (Bottom) Immunohistochemical stains from a second case show the nodular growth
pattern with strong staining for CD20, but also positivity for CD30 and focal staining for CD15. (C) Reclassified case: primary mediastinal large B cell lymphoma. Diffuse proliferation
of large neoplastic cells is seen (top left). The neoplastic cells have abundant clear cytoplasm and vesicular nuclei with basophilic nucleoli (top right). They are strongly, uniformly
positive for CD20, with dim expression of CD30, and are negative for CD15 (bottom). (D) Synopsis of the immunohistochemical staining results from consensus confirmed GZL
cases. The bar graph illustrates immunohistochemical staining for markers CD20, CD79a, PAX5, MUM1, CD30, CD15, CD3, and in situ hybridization for EBV (EBV-encoded small
RNA [EBER]). For immunohistochemical studies, staining was considered to be positive if it had intensity of 2 or more (on 11 to 13 scale) and was distributed in more than 25%
of neoplastic cells. Cases with weak/negative expression are not included in this graph. Hematoxylin and eosin staining, original magnification 3400 (A, B [top right panel], and
C [top panels]) and 3200 (B [top left panel]). Immunohistochemical staining, original magnification 3400 (all other panels).
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Figure 2. Survival. The 3-year (A) PFS of 25 patients with GZL compared with 36 reclassified lymphoma cases was 39% and 58%, respectively (P 5 .19), and
corresponding 3-year (B) OS was 95% and 85%, respectively (P 5 .15). Kaplan-Meier curves comparing PFS (C) and OS (D) for cHL NS2 vs cHL vs DLBCL; 3-year PFS
rates were 43%, 65%, and 67% (P 5 .67), respectively, and 3-year OS rates were 83%, 88%, and 71%, respectively (P 5 .80). The outcome (E) for patients with GZL based
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Treatment
Among GZL confirmed cases, the most common chemotherapy
regimen given was cyclophosphamide, doxorubicin, vincristine, and
prednisone6 rituximab (CHOP6R) therapy, given to 17/25 (68%) of
patients; 15 of these 17 patients received rituximab with CHOP. Six
of 25 patients with GZL received doxorubicin, bleomycin, vinblastine,
and dacarbazine (ABVD), 2 with rituximab, and 2 patients received
dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincris-
tine, prednisone, and rituximab (DA-EPOCH-R). Overall response
rate (ORR) among all patients with GZL was 60% with a complete
remission rate of 56% (ORR by therapy: ABVD6R, 33%; CHOP6R,
71%; EPOCH-R, 50%); 8% had stable disease, and 32% had
progressive disease/primary refractory. Among 12 patients with
GZL who had relapsed or refractory disease, 9 proceeded to
salvage therapy followed by autologous hematopoietic stem cell
transplant.
CHOP was also the most common therapeutic regimen for the
reclassified cases given to 17/36 (47%) patients (16/17 with
rituximab). Ten patients with reclassified lymphomas received
ABVD (none with rituximab), whereas 4 received DA-EPOCH-R;
2 bleomycin, etoposide, adriamycin, cyclophosphamide, oncovin,
procarbazine, and prednisone (BEACOPP); and 1 patient received
ifosfamide, carboplatin, and etoposide (ICE). All the latter 7 patients
received concurrent rituximab. Among data available on 9 patients
reclassified to cHL NS2, 4 received ABVD6R, 4 CHOP-R, and 1
DA-EPOCH-R. ORR for reclassified cases was 67% with 56%
complete remission (ORR by therapy: ABVD6R, 60%; CHOP6R,
65%; EPOCH-R, 75%; other: 100%); 31% had primary refractory
disease. Among 18 reclassified patients who had relapsed or
refractory disease, 12 had salvage therapy and hematopoietic stem
cell transplant (n 5 9 autologous and n 5 3 allogeneic).
Survival
With a median follow-up of 44 months (range, 8-120 months), the
3-year PFS and OS for GZL consensus patients were 39% and
95%, respectively (Figure 2). This compared with 3-year PFS and
OS for reclassified patients of 58% and 85%, respectively (P5 .19
and P 5 .15, respectively). Among the histologies within the
reclassified group, cHL NS2 appeared to have inferior PFS as
compared with cHL and DLBCL (Figure 2), with outcomes more
similar to consensus-confirmed GZL cases.
Prognostication
We studied a multitude of pathologic and clinical variables for
potential prognostication of outcome of patients with GZL. From
the immunohistochemistry markers examined (ie, CD20, CD79a,
PAX5, BCL6, MUM1, CD30, and CD15) and analyzing across
several different cut-points among these markers, only strong PAX5
expression (ie, 3 vs # 2: HR, 4.25; 95% CI, 1.09-16.60; P 5 .037)
and moderate to strong expression of CD30 (ie, 2-3 vs # 1: HR,
7.56; 95% CI, 1.000-58.83; P 5 .05) were associated with inferior
PFS. Among clinical variables on univariate analyses (Table 2),
serum albumin was significantly associated with patient outcome,
and sex was of borderline significance (ie, male improved PFS).
Examining the effect of treatment regimen on univariate analysis,
use of CHOP6R was associated with improved PFS and receipt of
radiotherapy was borderline; use of ABVD6R and DA-EPOCH-R
predicted for inferior outcome, although only 2 patients with GZL
were treated with the latter regimen in this series, and thus cannot
be reliably assessed. Use of rituximab was not statistically
significant on univariate analysis, but trended toward improved
PFS (HR, 0.37; P 5 .08; 95% CI, 0.12-1.13).
On Cox regression multivariable analysis, PAX5 lost statistical
significance while increased CD30 expression was borderline in
predicting inferior PFS (HR, 7.08; 95% CI, 0.88-57.27; P 5 .06)
(Figure 2E). Among clinical variables, albumin was the only factor
associated with patient survival (ie, hypoalbuminemia: PFS HR, 5.54;
95%CI, 1.16-26.42;P5 .03), and receipt with CHOP6R for frontline
therapy also remained significant when controlling for albumin and
Table 2. Factors predictive of PFS (univariate analysis)
4-year PFS
HR
95% HR
confidence
limits
PLow High
Baseline clinical factors
Age (continuous) 0.99 0.96 1.03 .75
Sex (male vs female) 0.35 0.12 1.08 .06
B symptoms (yes vs no) 2.47 0.75 8.16 .13
BMI (median) 1.00 0.86 1.16 .99
ECOG performance status (2-4 vs 0-1) 1.40 0.42 4.70 .58
Hemoglobin , 10.5 g/dL (no vs yes) 0.79 0.24 2.61 .70
LDH (creased vs normal) 1.71 0.48 6.16 .40
ESR (increased vs normal) 1.77 0.16 19.63 .63
Albumin , 4.0 g/dL (yes vs no) 5.06 1.11 23.19 .03
Primary mediastinal disease (yes vs no) 0.42 0.14 1.26 .12
Bulky disease (yes vs no) 0.33 0.07 1.53 .15
Stage at diagnosis (1-2 vs 3-4) 0.80 0.25 2.63 .72
Prognostic score, IPI (continuous) 1.28 0.63 2.61 .49
Prognostic score, IPS (continuous) 1.49 0.65 3.42 .34
Treatment factors
Rituximab (yes vs no) 0.36 0.12 1.13 .08
ABVD (yes vs no) 2.72 0.88 8.42 .08
CHOP (yes vs no) 0.22 0.02 0.53 .008
EPOCH (yes vs no) 6.55 1.28 33.45 .02
Consolidative radiotherapy (yes vs no) 0.36 0.12 1.14 .08
Bold values indicate factors that are statistically significant. The following variables had
too few events to provide an accurate estimate for Cox overall survival models: bone
marrow involved (yes vs no), creatinine at diagnosis (increased vs normal), more
than 1 extranodal site (yes vs no).
ECOG, Eastern Cooperative Oncology Group; ESR, erythrocyte sedimentation rate.
Figure 2. (continued) on CD30 expression was 3-year PFS of 83% for Neg-1 vs 34% for 2-3 on immunohistochemistry; (F) the 3-year PFS for patients with hypoalbuminemia
vs normal albumin were 64% vs 12% (P 5 .01). Kaplan-Meier curves (G) for patients who received CHOP6R therapy for frontline therapy vs not; 3-year PFS was 70% vs
20%, respectively (P 5 .03). The 2 latter findings persisted on multivariable Cox regression analysis.
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International Prognostic Index (PFS HR, 0.017; 95%CI, 0.001-0.319;
P5 .006), as also depicted via Kaplan-Meier curves in Figures 2F-G.
Discussion
The entity of GZL sharing features with both cHL and DLBCL was
first formulated at a joint workshop on cHL,19 with a successive
series published from the National Cancer Institute in 2005.1 It
was subsequently included in the 2008 WHO classification of
lymphoid neoplasms.1,2,3,10,20 A retrospective analysis of 112 GZL
cases diagnosed and treated across 19 North American academic
centers described clinical features and outcomes of GZL treated in
the contemporary era, including the majority of cases presenting
with systemic disease without mediastinal disease and PFS rates
comparatively inferior compared with cHL or DLBCL.5 Further,
there was a suggestion of improved outcomes with use of
regimens typically used for DLBCL, rather than cHL. A critical
limitation of this retrospective study, however, was the lack of
centralized pathology review. Slides from the majority of these
previously reported GZL cases were obtained, and centralized
pathologic consensus review was undertaken, together with
analyses of all associated clinical data. To the best of our
knowledge, this is the largest clinical-pathologic consensus study
conducted to date on GZL.
Remarkably, less than 40% of the original cases diagnosed as
GZL in the recent multicenter retrospective study had this
diagnosis confirmed on pathologic consensus review, with the
majority of cases being reclassified to a different lymphoma
diagnosis. Despite all original cases being diagnosed and treated
at mostly large academic medical centers with excellent hematopa-
thology expertise, this result underscores the modest interobserver
agreement and continued complexity of pathologic diagnosis of
GZL. Collectively, morphology remains a critical initial method in the
diagnosis of GZL, with immunohistochemistry and in situ hybridiza-
tion for EBV providing key diagnostic parameters. Other ancillary
testing (eg, flow cytometry or molecular studies) does not contribute
substantially to the diagnosis at this time. Furthermore, caution
should be applied to tissue with limited material and limited number
of neoplastic cells.
A spectrum of morphologies with features of cHL and PMBL can
occur in GZL, and divergent morphologic areas may be seen within
the same tumor specimen. An important morphologic feature of
GZL is the abundance of tumor cells, often with confluent sheets of
tumor cells. In general, the neoplastic cells in GZL occur in a
background containing a paucity of inflammatory cells, although
eosinophils, histiocytes, and small lymphocytes can be seen.
Variable fibrosis can be present, including extensive coarse fibrosis
as well as fine compartmentalizing fibrosis. Nuclear cytomorphology
in GZL is an important feature because the neoplastic cell nuclei
exhibit a broader range in size and shape, with more infrequent
eosinophilic nucleoli, than the Hodgkin Reed Sternberg cells and
variants of cHL.
Similar to morphologic findings, the immunophenotype of GZL is
variable with transitional and divergent patterns (ie, tumors with
cHL-like morphology can exhibit classic DLBCL or PMBL
immunophenotype, and vice versa). Tumors resembling cHL may
show prominent CD20, weaker/absent CD30, and absent CD15,
whereas tumors resembling PMBL are frequently strongly positive
for CD30 and CD15 with negativity of CD20 and CD79a. All GZL
cases were of B-cell derivation showing expression of at least 1
B-cell marker; CD20 was positive in all but 4 GZL cases, and all
neoplastic cells in GZL invariably expressed MUM1. This feature, in
conjunction with nuclear cytomorphology, can be helpful in
highlighting neoplastic cell nuclei within the inflammatory or fibrotic
background. CD30 positivity was a common finding and, if seen in
conjunction with CD15 and PMBL morphology, should raise
suspicion for GZL. Altogether, based on consensus opinion, the
minimum immunohistochemical panel considered adequate for
diagnosis should include CD20, PAX5, MUM1, CD30, CD15, and
EBV by in situ hybridization; these recommendations, along with an
advocated diagnostic algorithm, are detailed in Figure 3.
Most of the reclassified cases fell into the category of cHL NS.
Strong expression of CD20 on the neoplastic cells likely
contributed the diagnosis of GZL in a large subset of these, but
the low tumor cell content, Hodgkin Reed Sternberg cell
morphology, and inflammatory background favored cHL NS.
Notably, expression of CD20 in a tumor otherwise typical of cHL
should not lead to a diagnosis of GZL. Moreover, the NS2 subtype
of cHL was relatively frequently among reclassified cases. The NS2
variant of NSHL, also known as cHL NS with lymphocyte depletion,
tracks back several decades to original work at the National Cancer
Institute, and subsequently at the British National Lymphoma
Investigation, where it was identified as a subset with aggressive
behavior and poor prognosis in several studies.17,18,21,22 Although
knowledge of various morphologic subtypes of cHL and historical
perspective on nomenclature development are helpful in under-
standing different entities, this became less relevant with improved
treatment,23 and the WHO does not currently mandate grading of
cHL NS in routine clinical practice. However, it is important to be
aware of the morphological spectrum within cHL NS to avoid
misinterpretation of these cases. Biopsies diagnosed as cHL NS2
showed fibrosis with at least a partially nodular growth pattern and a
high content of Hodgkin Reed Sternberg cells, often palisaded
around areas of necrosis with frequent eosinophils and neutrophils.
It should be noted that the extent of necrosis often tends to correlate
with burden of neoplastic cells.24 cHL NS2 may resemble GZL in
those cases showing confluent growth of lacunar cells in a relatively
paucicellular fibrotic stroma.
Gene expression studies have shown common features between
PMBL and cHL, including some common genetic findings among
these tumors.25-27 Further studies showed similar genetic aberra-
tions in GZL,10 although methylation profiling still revealed that cHL,
GZL, and DLBCL clustered separately by principle component
analysis.20 Biologic analyses to compare the cases of cHL NS2 and
GZL were beyond the scope of the current study, in part as samples
were limited from this large retrospective series drawn from many
different centers. Interestingly, the relatively poor outcomes for
patients with cHL NS2 here appeared similar to the patients with
consensus GZL in this analysis (ie, 3-year PFS rates of 39% and
43%, respectively); however, the patients with cHL NS2 likely did
not receive optimal HL-directed therapy, given the original diagnosis
of GZL with DLBCL-directed therapy in the majority of those cases.
Clinically, the median age, stage, and incidence of bulk disease of
the current cohort of patients with GZL consensus is similar to that
of other recent reports of GZL.28 The majority of patients with GZL
here also had early-stage disease, and 70% had primary mediastinal
disease; a minority of patients had nonmediastinal, systemic disease,
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which is a change from the prior report,5 where this was the more
common clinical presentation. However, it is still important to highlight
that either clinical presentation may be encountered with GZL. Cases
with consensus GZL without mediastinal disease were older both in
the current study and prior published series.10 Regardless of clinical
presentation, however, PFS appears to be inferior compared with
DLBCL or cHL patient populations.
Therapy was fairly heterogeneous among the consensus GZL
cases; however, patients were primarily treated according to either
a cHL-like (eg, ABVD) or DLBCL-like (eg, CHOP6R) paradigm.
Among all patients with GZL here, a significant minority of patients
had primary refractory disease to frontline therapy. In addition, PFS
was best for patients with GZL treated according to a DLBCL
regimen. Further, CHOP6R appeared to be the optimal chemo-
therapy regimen in this analysis; however, definitive conclusions are
tempered because of a small number of patients treated with other
therapeutic regimens. A recent French series of GZL reported
improved outcomes for patients treated with more intensive
therapeutic regimens (ie, methylprednisolone, doxorubicin, cy-
clophosphamide, procarbazine, etoposide, bleomycin, vincristine
(escBEACOPP) or doxorubicin, methylprednisolone, cyclophos-
phamide, bleomycin, vindesine.29 It is unclear whether these more
dose-intensive regimens are needed for therapy of GZL. It should
be highlighted that 3-year event-free survival rates for these regimens
were 73% and 70%, respectively, which compares with the 71%
PFS rate for patients who received CHOP6R in the current series. In
both series, the majority of patients had early-stage disease.
Nevertheless, the excellent OS in the current and other series,
including good outcomes with second-line therapy for patients with
GZL (with hematopoietic stem cell transplant in the majority of cases)
suggests more intensive therapeutic platforms may play a role in the
management of this disease.
Prognostically, increased PAX5 or moderate/strong CD30 expres-
sion was associated with inferior PFS in consensus patients with
GZL. CD30 expression has been shown to be a favorable prognostic
factor in DLBCL,30 although some series have shown conflicting
data.31 In part, given that weak or absent CD30 staining was relatively
uncommon in the current series, this observation warrants confirma-
tion. We were not able to confirm the prognostic importance of
CD15 staining as shown before.28 In addition, we did not test for
• Tissue should include significant number of 
neoplastic cells (high tumor cell content) and 
associated stromal background. 
• Although the minimum number of neoplastic cells 
is difficult to define, FNA, core biopsy of a 
mass/node or bone marrow biopsy or a small 
endoscopic biopsy with rare neoplastic cells are 
not usually adequate. 
Determine if quantity
of tissue is adequate
for diagnosis
• GZL lacks the typical architectural features of cHL 
NS, including nodular growth pattern and well-
formed fibrous bands, although focal fibrosis may 
be present.  
• Tumor cell density is high.
Diagnosis of GZL
requires evaluation
of both architectural
and cytological
features
• Key feature of GZL is broad cytological spectrum.
• While occasional cells may resemble HRS cells, 
there is wide range of cytology, including some 
cells with centroblastic or immunoblastic cytology.  
• Marked nuclear pleomorphism is characteristic.  
• A small subset of GZL cases have more 
monomorphic cytology, resembling PMBL, but 
lack a B-cell phenotype.
Confirm that
cytomorphology is
compatible with GZL
• Most cases of GZL show strong expression of 
CD20, CD30 and MUM1. 
• However, a smaller subset of GZL cases may 
resemble PMBL, but show loss of CD20.
Immunophenotype
may vary
PITFALLS
If overall features are typical for cHL NS, CD20 expression on
even majority of HRS cells is insufficient for GZL diagnosis; this
includes cases with both low tumor cell content and higher tumor
cell content (i.e., cHL-NSG2) all of which maintain a nodular
growth pattern and characteristic inflammatory background.
If EBV is positive in neoplastic cells, consider other EBV-driven
B-cell lymphoproliferative disorders.
These guidelines apply to primary diagnostic biopsies and not
recurrences post-treatment.
Figure 3. GZL diagnostic algorithm. The minimum diagnostic
panel for workup of GZL should include B-cell markers (CD20 and
PAX5), MUM1, CD30, and CD15. A broad panel of T-cell and
cytotoxic markers is desirable to rule out anaplastic large
cell lymphoma. EBV by in situ hybridization should also be a part
of the diagnostic panel. (Top) Stepwise approach to the diagnostic
evaluation of GZL. (Lower balloon) depicts potential pitfalls in
the diagnostic evaluation of GZL to also consider. FNA, fine
needle aspiration.
12 DECEMBER 2017 x VOLUME 1, NUMBER 26 A CONSENSUS STUDY OF GRAY ZONE LYMPHOMA 2607
the presence of tumor-infiltrating dendritic cells in this current
analysis. Clinically, serum albumin was the only factor significantly
associated with patient outcome with presence of hypoalbuminemia
at diagnosis being associated with 5-fold increased risk for progres-
sion. This is a clinical factor that has been shown to be prognostic in
HL as well as non-Hodgkin lymphomas.32-38 However, the small
number of patients and relative heterogeneity of therapy limit
conclusions regarding prognostication.
In summary, the pathologic diagnosis of GZL remains challenging.
Only 38% of cases were confirmed on central pathology review. High
tumor cell content is very helpful when differentiating between GZL
and cHL, the most common alternative diagnosis in this series. A
spectrum of morphologies with cHL and PMBL can occur, and
divergent morphologic areas can be seen within the same tumor.
CD30 expression was common, whereas EBV positivity was rare.
Accurate diagnosis is a prerequisite for selection of optimal treatment
because current therapeutic strategies for cHL NS, the entity most
commonly misdiagnosed as GZL, are different. The small number of
patients and relative heterogeneity of therapy limit definitive de-
lineation of optimal therapy for GZL; however, our results suggest that
treatment with DLBCL-based regimens is most effective, including
R-CHOP as well as DA-EPOCH-R, the latter as reported pre-
viously.28 Finally, we identified clinical factors that identified patients
with GZL with divergent clinical outcomes. Continued analysis of
clinical and pathological features is required to better identify the most
important prognostic and biologic factors of GZL. In addition, rational
targeted therapeutic agents should be studied in this disease.
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